Loading…
Loading…
do you see this competitive advantage as stable or expanding, weakening, entering this year
how are you feeling about industry supplied demand dynamics entering 2026
just great to get your latest thoughts on how you felt like you were tracking relative to that
any additional color you can share on trends and new authorizations, how you feel like pharma customers are feeling about getting back to work
just the organic growth decline this quarter. When you talk about some of the policy pressure, was this all academic
did you see any evidence customers could have been pausing purchasing at all? Just the idea being like if you're going to buy equipment
what inning you think this business is now in kind of in the post-COVID recovery, confidence that continues
Curious what you're hearing from customers and then just talk about the risks and opportunities there for Thermo Fisher Scientific
what does the guide assume for PPD clinical research? And can you give us an update, just color on what you're seeing in terms of new authorizations
what does the exit rate look like in the fourth quarter? And just more broadly, just like confidence about your ability to get back to the LRP targets